On Thursday, Shares of WhiteWave Foods Co (NYSE:WWAV), subtract -0.95% and closed at $53.95 in the last trading session. The last trading range of the stock ranges between $53.73 and $54.32. The WhiteWave Foods Company (WWAV) recently stated financial results for the third quarter ended September 30, 2016.
WhiteWave’s third quarter 2016 stated diluted earnings per share was $0.32 and adjusted diluted earnings per share was $0.37, apart from operating costs associated with its China joint venture. Counting joint venture costs, WhiteWave stated third quarter 2016 adjusted diluted earnings per share of $0.35.
Net sales for third quarter 2016 were $1.1 billion, a 5 percent increase from net sales of $1.0 billion in third quarter 2015. These results were driven by organic growth and acquisitions within the last year, partially offset by Fresh Foods platform results and unfavorable currency impacts. On a constant currency basis, net sales raised 6 percent in third quarter 2016, when contrast to third quarter 2015. Apart From acquisitions, organic constant currency net sales raised 3 percent in third quarter 2016.
Amarin Corporation plc (ADR)(NASDAQ:AMRN), dropped -0.96% and closed at $3.08 in the last trading session. The last trading range of the stock ranges between $3.02 and $3.19. The company’s Market capitalization is $879.37 million with the total Outstanding Shares of 269.95 million. Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, recently declared financial results for the three and nine months ended September 30, 2016, and offered an update on company operations.
Key Amarin achievements since June 30, 2016 include:
Revenue growth: Recognized $32.4 million in net product revenue from Vascepa® (icosapent ethyl) sales in Q3 2016 contrast to $21.3 million in Q3 2015, a boost of 52%.
Prescription growth: Raised normalized prescriptions, based on data from Symphony Health Solutions and IMS Health, by 54% and 56%, respectively, contrast to Q3 2015.
R&D progress: REDUCE-IT cardiovascular outcomes study continues to track towards achieving, before the end of 2017, the onset of the targeted 1,612 aggregate primary cardiovascular events for completion of the study. As expected, no modification to the study was recommended based on the first pre-specified interim efficacy analysis, the “60% review” as accomplished in September by the study’s independent data monitoring committee (DMC).
Healthcare Trust Of America Inc (NYSE:HTA), dropped -3.81% and closed at $27.32 in the last trading session. The last trading range of the stock ranges between $36.34 and $28.31. During the 52-week trading session the minimum price at which share price traded, registered at $24.00 and reached to max level of $34.64. Healthcare Trust of America, Inc. is a publicly owned equity real estate investment trust. The firm invests in the real estate markets of the United States. It is engaged in acquiring, owning and operating high-quality medical office buildings located mainly on-campus or associated with the nations leading healthcare systems.